Wyeth’s desvenlafaxine reduces vasomotor symptoms in menopausal women
According to the company, this significant reduction was seen as early as week one. The common adverse drug reactions (greater than or equal to 5% of either desvenlafaxine
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.
ALO-01 (extended-release morphine sulfate plus sequestered naltrexone) showed similar effectiveness to Alpharma’s extended-release oral formulation of morphine sulfate, Kadian, and maintained pain reduction throughout the study. The sequestered